Fig. 1 · Structure

Documents & Downloads

Asaraldehyde (Asaronaldehyde)

Cat. No. A10090 CAS 4460-86-0

COX-2 inhibitor

Asaraldehyde is a selective COX-2 inhibitor.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
COX-2  

Asaraldehyde (Asaronaldehyde) Research Summary

This section summarizes 2 in vitro studies of Asaraldehyde (Asaronaldehyde) from 1 published reference. In vitro models include A23187-stimulated rat basophilic leukemia RBL-1 cells.

Asaraldehyde (Asaronaldehyde) In Vitro Studies

In an Acorus gramineus constituent screen, asaraldehyde showed weak inhibition of antigen-induced β-hexosaminidase release in RBL-2H3 cells (12.9% at 50 μM; arithmetic mean, n=3). In the separate RBL-1 cellular assay, it was reported as not active against A23187-stimulated cysteinyl-leukotriene production at 50 μM. These results are specific to the reported assay conditions and do not establish a degranulation IC50 or direct 5-LOX inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular leukotriene production screen

Cell-based study · A23187-stimulated rat basophilic leukemia RBL-1 cells [1]

Asaraldehyde was reported as not active at 50 μM in the cellular cysteinyl-leukotriene production screen. This is a cellular pathway endpoint, not a purified 5-LOX binding or enzyme-selectivity assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of cysteinyl-leukotriene (LTC4/D4/E4) productionActivity at 50 μM − (not active); n=3[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM asaraldehyde; 3 μM A23187 stimulus
Exposure duration
10 min compound preincubation, followed by 15 min with A23187
Method
Compound pretreatment followed by calcium-ionophore stimulation; cysteinyl-leukotrienes measured by ELISA.
Vehicle
DMSO, final 0.1% (v/v)
Co-treatment
A23187 stimulation is part of the assay; no therapeutic combination evaluated.
Reported limits
No numeric inhibition value or uncertainty is given for the inactive asaraldehyde entry; n=3 is reported without specifying independent biological versus technical replicates.
Methods and source locations

Compound reported in the paper: Asaraldehyde; Compound label in the paper: Compound 2

Findings concern the reported plant-derived isolate; they do not validate the purity or performance of an Adooq lot.

Table 1; Materials and Methods, RBL-1 cell culture and measurement of LT concentration; Results, first paragraph; Figure 2 caption

Inhibition of cysteinyl-leukotriene (LTC4/D4/E4) production: ELISA of culture medium; Table 1 footnote c defines the dash as not active. No exact percentage is assigned. — Table 1, Asaraldehyde row, 5-LOX column; footnotes a and c

Antigen-induced mast-cell degranulation screen

Cell-based study · IgE-sensitized rat basophilic leukemia RBL-2H3 cells challenged with DNP-BSA [1]

Asaraldehyde produced 12.9% inhibition of antigen-induced β-hexosaminidase release at 50 μM. The authors described this as weak activity. This single-concentration result does not establish an IC50 or a direct molecular target.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of antigen-induced β-hexosaminidase release% inhibition at 50 μM 12.9%; arithmetic mean, n=3[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM asaraldehyde; 1 μg/ml DNP-BSA antigen
Exposure duration
Overnight IgE sensitization; 30 min compound incubation; 10 min antigen challenge
Method
IgE sensitization followed by compound pretreatment and DNP-BSA challenge; released enzyme measured with p-nitrophenyl-N-acetyl-β-D-glucosaminide.
Vehicle
DMSO; final percentage not specified in the RBL-2H3 methods subsection.
Co-treatment
Anti-DNP IgE and DNP-BSA are assay sensitization/challenge reagents, not therapeutic combination agents.
Reported limits
No asaraldehyde IC50, variance or significance test is supplied in Table 1. Do not transfer the 0.1% DMSO condition from the distinct RBL-1 assay.
Methods and source locations

Compound reported in the paper: Asaraldehyde; Compound label in the paper: Compound 2

Findings concern the reported plant-derived isolate; they do not validate the purity or performance of an Adooq lot.

Table 1; Materials and Methods, RBL-2H3 cell culture and antigen-induced degranulation; Results, degranulation paragraphs; Figure 3 caption

Inhibition of antigen-induced β-hexosaminidase release: Colorimetric substrate assay at 405 nm on supernatant after antigen challenge; no uncertainty reported for this table entry. — Table 1, Asaraldehyde row, β-hexosaminidase column; footnote a

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 4460-86-0
Applications COX-2 inhibitor
Formula C10H12O4
Molecular Weight 196.2
Synonyms Asarylaldehyde; NSC 89299; Asaronaldehyde
SMILES
COC1=CC(=C(C=C1C=O)OC)OC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 35 mg/mL (178.38 mM)
Water Insoluble
Ethanol 14 mg/mL (71.35 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Asaraldehyde (Asaronaldehyde) Research References

  1. [1] Hyun Lim, Seung Young Lee, Kang Ro Lee, et al. The Rhizomes of Acorus gramineus and the Constituents Inhibit Allergic Response In vitro and In vivo Biomolecules & Therapeutics (2012). PMID: 24009837 DOI: 10.4062/biomolther.2012.20.5.477 Source material

Added to your cart

View Cart Checkout
Loading...